Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: RECEPTOR, ERBB-2 - METABOLISM , . Treffer: 26

2019

Schmoeckel, E; Hofmann, S; Fromberger, D; Rottmann, M; Luthardt, B; Burges, A; Jeschke, U; Kirchner, T; Lax, SF; Mayr, D Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.
Virchows Arch. 2019; 474(5):599-608
Web of Science PubMed FullText FullText_MUG

 

2017

Schramm, A; Schochter, F; Friedl, TWP; de Gregorio, N; Andergassen, U; Alunni-Fabbroni, M; Trapp, E; Jaeger, B; Heinrich, G; Camara, O; Decker, T; Ober, A; Mahner, S; Fehm, TN; Pantel, K; Fasching, PA; Schneeweiss, A; Janni, W; Rack, BK; SUCCESS Study Group Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Clin Breast Cancer. 2017; 17(4):279-285
Web of Science PubMed FullText FullText_MUG

 

2016

Grillo, F; Fassan, M; Sarocchi, F; Fiocca, R; Mastracci, L HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice.
World J Gastroenterol. 2016; 22(26):5879-5887 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Kammerer, S; Sokolowski, A; Hackl, H; Platzer, D; Jahn, SW; El-Heliebi, A; Schwarzenbacher, D; Stiegelbauer, V; Pichler, M; Rezania, S; Fiegl, H; Peintinger, F; Regitnig, P; Hoefler, G; Schreibmayer, W; Bauernhofer, T KCNJ3 is a new independent prognostic marker for estrogen receptor positive breast cancer patients.
Oncotarget. 2016; 7(51):84705-84717 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Schramm, A; Friedl, TW; Schochter, F; Scholz, C; de Gregorio, N; Huober, J; Rack, B; Trapp, E; Alunni-Fabbroni, M; Müller, V; Schneeweiss, A; Pantel, K; Meier-Stiegen, F; Hartkopf, A; Taran, FA; Wallwiener, D; Janni, W; Fehm, T Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.
Arch Gynecol Obstet. 2016; 293(2):271-281
Web of Science PubMed FullText FullText_MUG

 

Sysa-Shah, P; Tocchetti, CG; Gupta, M; Rainer, PP; Shen, X; Kang, BH; Belmonte, F; Li, J; Xu, Y; Guo, X; Bedja, D; Gao, WD; Paolocci, N; Rath, R; Sawyer, DB; Naga Prasad, SV; Gabrielson, K Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways.
Cardiovasc Res. 2016; 109(3):358-373 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2015

Bollen, L; Wibmer, C; Wang, M; van der Linden, YM; Leithner, A; Bünger, CE; Jensen, AB; Fiocco, M; Bratschitsch, G; Pondaag, W; Bovée, JV; Dijkstra, PD Molecular phenotype is associated with survival in breast cancer patients with spinal bone metastases.
Clin Exp Metastasis. 2015; 32(1):1-5
Web of Science PubMed FullText FullText_MUG

 

Pircher, M; Mlineritsch, B; Fridrik, MA; Dittrich, C; Lang, A; Petru, E; Weltermann, A; Thaler, J; Hufnagl, C; Gampenrieder, SP; Rinnerthaler, G; Ressler, S; Ulmer, H; Greil, R Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
Anticancer Res. 2015; 35(1):517-521
Web of Science PubMed

 

Widschwendter, P; Friedl, TW; Schwentner, L; DeGregorio, N; Jaeger, B; Schramm, A; Bekes, I; Deniz, M; Lato, K; Weissenbacher, T; Kost, B; Andergassen, U; Jueckstock, J; Neugebauer, J; Trapp, E; Fasching, PA; Beckmann, MW; Schneeweiss, A; Schrader, I; Rack, B; Janni, W; Scholz, C The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial.
Breast Cancer Res. 2015; 17(4):129-129 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2014

Gnant, M; Filipits, M; Greil, R; Stoeger, H; Rudas, M; Bago-Horvath, Z; Mlineritsch, B; Kwasny, W; Knauer, M; Singer, C; Jakesz, R; Dubsky, P; Fitzal, F; Bartsch, R; Steger, G; Balic, M; Ressler, S; Cowens, JW; Storhoff, J; Ferree, S; Schaper, C; Liu, S; Fesl, C; Nielsen, TO; Austrian Breast and Colorectal Cancer Study Group Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
Ann Oncol. 2014; 25(2):339-345 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Puzovic, V; Brcic, I; Ranogajec, I; Jakic-Razumovic, J Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients.
Neoplasma. 2014; 61(4): 439-446. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2013

Dubsky, P; Filipits, M; Jakesz, R; Rudas, M; Singer, CF; Greil, R; Dietze, O; Luisser, I; Klug, E; Sedivy, R; Bachner, M; Mayr, D; Schmidt, M; Gehrmann, MC; Petry, C; Weber, KE; Kronenwett, R; Brase, JC; Gnant, M; Austrian Breast and Colorectal Cancer Study Group (ABCSG). EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Ann Oncol. 2013; 24(3):640-647 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2012

Labonte, MJ; Wilson, PM; Yang, D; Zhang, W; Ladner, RD; Ning, Y; Gerger, A; Bohanes, PO; Benhaim, L; El-Khoueiry, R; El-Khoueiry, A; Lenz, HJ The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.
Ann Oncol. 2012; 23(6):1455-1464 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2011

Shalaby, A; Presneau, N; Ye, H; Halai, D; Berisha, F; Idowu, B; Leithner, A; Liegl, B; Briggs, TR; Bacsi, K; Kindblom, LG; Athanasou, N; Amary, MF; Hogendoorn, PC; Tirabosco, R; Flanagan, AM The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
J Pathol. 2011; 223(3): 336-346.
Web of Science PubMed FullText FullText_MUG

 

2010

Erdman, SE; Rao, VP; Olipitz, W; Taylor, CL; Jackson, EA; Levkovich, T; Lee, CW; Horwitz, BH; Fox, JG; Ge, ZM; Poutahidis, T Unifying roles for regulatory T cells and inflammation in cancer.
Int J Cancer. 2010; 126(7):1651-1665 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2009

Gonzalez-Angulo, AM; Litton, JK; Broglio, KR; Meric-Bernstam, F; Rakkhit, R; Cardoso, F; Peintinger, F; Hanrahan, EO; Sahin, A; Guray, M; Larsimont, D; Feoli, F; Stranzl, H; Buchholz, TA; Valero, V; Theriault, R; Piccart-Gebhart, M; Ravdin, PM; Berry, DA; Hortobagyi, GN High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
J Clin Oncol. 2009; 27(34):5700-5706 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Reim, F; Dombrowski, Y; Ritter, C; Buttmann, M; Hausler, S; Ossadnik, M; Krockenberger, M; Beier, D; Beier, CP; Dietl, J; Becker, JC; Honig, A; Wischhusen, J Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
Cancer Res. 2009; 69(20):8058-8066 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2008

Brunner, M; Thurnher, D; Pammer, J; Geleff, S; Heiduschka, G; Reinisch, CM; Petzelbauer, P; Erovic, BM Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma.
Mod Pathol. 2008; 21(7):876-884 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Mlineritsch, B; Tausch, C; Singer, C; Luschin-Ebengreuth, G; Jakesz, R; Ploner, F; Stierer, M; Melbinger, E; Menzel, C; Urbania, A; Fridrik, M; Steger, G; Wohlmuth, P; Gnant, M; Greil, R; on behalf of the Austrian Breast, Colorectal Cancer Study Group (ABCSG) Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17).
Breast Cancer Res Treat. 2008; 112(1): 203-213.
Web of Science PubMed FullText FullText_MUG

 

Reiner-Concin, A; Regitnig, P; Dinges, HP; Höfler, G; Lax, S; Müller-Holzner, E; Obrist, P; Rudas, M Practice of HER-2 immunohistochemistry in breast carcinoma in Austria.
Pathol Oncol Res. 2008; 14(3):253-259
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2007

Schippinger, W; Dandachi, N; Regitnig, P; Hofmann, G; Balic, M; Neumann, R; Samonigg, H; Bauernhofer, T The predictive value of EGFR and HER-2/neu in tumor tissue and serum for response to anthracycline-based neoadjuvant chemotherapy of breast cancer.
Am J Clin Pathol. 2007; 128(4):630-637 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2006

Haberler, C; Slavc, I; Czech, T; Gelpi, E; Heinzl, H; Budka, H; Urban, C; Scarpatetti, M; Ebetsberger-Dachs, G; Schindler, C; Jones, N; Klein-Franke, A; Maier, H; Jauk, B; Kiefer, A; Hainfellner, JA Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome.
Eur J Cancer. 2006; 42(17):2996-3003
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2005

Leibl, S; Moinfar, F Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?
J CLIN PATHOL 2005 58: 700-704. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Reitsamer, R; Peintinger, F; Prokop, E; Hitzl, W Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.
Anticancer Drugs. 2005; 16(8): 867-870.
Web of Science PubMed FullText FullText_MUG

 

2002

Schindl, M; Schoppmann, SF; Samonigg, H; Hausmaninger, H; Kwasny, W; Gnant, M; Jakesz, R; Kubista, E; Birner, P; Oberhuber, G; Austrian Breast and Colorectal Cancer Study Group Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.
Clin Cancer Res. 2002; 8(6):1831-1837 [OPEN ACCESS]
Web of Science PubMed FullText

 

1997

Bauer, M; Horn, LC; Kowalzik, J; Mair, W; Czerwenka, K C-erbB-2 amplification and expression in gestational trophoblastic disease correlates with DNA content and karyotype.
Gen Diagn Pathol. 1997; 143(2-3):185-190
PubMed

 

© Med Uni Graz Impressum